Part:BBa_K4251003
PDRG1-SiRNA-1
RDRG1-SiRNA-1
Profile
Name: PRDG1-siRNA
Base Pairs: 21bp
Origin: Company synthetic
Properties: Silencing RNA of PDRG1
Contribution
siRNA is a double-stranded non-coding RNA molecule, it usually between 20 and 24 base pairs, and it is also known as silencing RNA and short interfering RNA. siRNAs have very tight target specificity, this anti-sense strand binds to the target mRNA, and then the target mRNA cleavage is induced. PRDG1-siRNA is designed according to the DNA sequence of PRDG1, and it’s 21bp long. We insert the siRNA into AgeI and EcoRI sites of the GV248 plasmid, and the correct plasmid was sent to the company for lentivirus packaging. The lentivirus was then transfected to T98G and U118 TMZ resistance cell line to knock down the PRDG1 transcripts.
Engineering Success
1. PDRG-1 knockdown cell-line construction
In order to verify if knockdown of the PDRG1 gene could decrease the TMZ-resistance cells’ lifespan, we transfected T98G cells and U118 cells with Lentivirus packaged plasmids containing siRNAs and screened them using purine. The fluorescence microscope can be used to check if the plasmids have been transfected successfully by detecting the green fluorescence (Figure 1).
To get more reliable and quantitative results, fluorescence real-time quantitative PCR was done to test the mRNA expression of PDRG1 in the transfection cell line (Figure 2). As shown below, the mRNA expression level of PDRG-1 is significantly lower in shRNA treated group (Table 2).
Table 1. Data of relative expression of PDRG-1 from qPCR.
4. PDRG-1 knockdown cell line PDRG1 protein expression level measurement
In addition, the Western blot was done to further confirm PDRG-1 expression on the protein level in each group. The thickness of the protein band indicates the amount of the expressed protein. GAPDH was used as a control group, as it is a common housekeeper gene. It can be easily observed that in the PDRG-1 group, the protein band of Lv-sh1 and Lv-sh2 are thinner than the Lv-shNC, showing the lowered expression of PDRG-1 in the experimental group (Figure 3).
Proof of function
5. TMZ tolerance test
The control group and the PDRG-1 knockdown group are treated with TMZ. The relative cell viability was recorded over 72 hours for U118 (Figure 4A) as well as T98G (Figure 4B). In both groups, there are significant differences between the control group and the PDRG-1 knockdown group. Comparatively, the PDRG-1 knockdown groups show lower cell viability over time and lower TMZ tolerance, which is our expected result.
Future plan
We have already collected the figures from our experiments. PDRG1 is a small oncogenic protein related to TMZ resistance. However, TMZ resistance may cause chemotherapy failure which significantly decreases the survival rates of GBM patients. To conquer this problem, we screened the databases to search for related genes that could be used as therapeutic targets, so PDRG1 was chosen for our project.
We constructed a PDRG1 knockdown cell line that has been shown to have a higher potential to counter TMZ tolerance. This cell line can be used to further investigate the PDRG signaling pathway to gain a deeper understanding of the molecular mechanisms of TMZ tolerance development and thereby inspire new research directions seeking to eliminate or moderate TMZ tolerance. We believe that if we can fully understand the mechanism of PDRG1 in the TMZ-resistance process, we could provide new ways to treat GBM.
Reference
1. Lee, S. Y. (2016, May 11). Temozolomide resistance in glioblastoma multiforme. Genes & Diseases. Retrieved July 26, 2022, from https://www.sciencedirect.com/science/article/pii/S2352304216300162
2. Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018, October 15). Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurologia medico-chirurgica. Retrieved July 26, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186761/
3. Kato, T., Natsume, A., Toda, H., Iwamizu, H., Sugita, T., Hachisu, R., Watanabe, R., Yuki, K., Motomura, K., Bankiewicz, K., & Wakabayashi, T. (2010, June 3). Efficient delivery of liposome-mediated MGMT-Sirna reinforces the cytotoxity of temozolomide in GBM-initiating cells. Nature News. Retrieved July 26, 2022, from https://www.nature.com/articles/gt201088
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
None |